Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Lowered to $211.00

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Rating) had its target price decreased by Citigroup from $223.00 to $211.00 in a research report issued on Friday, The Fly reports. Citigroup’s price target would indicate a potential upside of 47.11% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Morgan Stanley cut Alnylam Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $210.00 to $178.00 in a report on Monday, April 25th. SVB Leerink dropped their price target on Alnylam Pharmaceuticals from $109.00 to $103.00 and set a “market perform” rating on the stock in a research note on Friday, February 11th. Stifel Nicolaus reiterated a “buy” rating and set a $215.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday, March 24th. Guggenheim upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $170.00 price target on the stock in a research report on Thursday, February 3rd. Finally, Piper Sandler raised Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the company from $181.00 to $208.00 in a report on Monday, January 3rd. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $219.76.

ALNY stock traded up $4.38 during trading on Friday, reaching $143.43. The stock had a trading volume of 942,544 shares, compared to its average volume of 827,193. The firm has a market cap of $17.33 billion, a PE ratio of -19.08 and a beta of 0.95. The company has a current ratio of 4.27, a quick ratio of 4.14 and a debt-to-equity ratio of 1.69. The stock’s 50 day moving average is $160.03 and its two-hundred day moving average is $165.10. Alnylam Pharmaceuticals has a 52 week low of $125.00 and a 52 week high of $212.00.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Rating) last issued its earnings results on Thursday, April 28th. The biopharmaceutical company reported ($2.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.84) by ($0.16). Alnylam Pharmaceuticals had a negative net margin of 101.46% and a negative return on equity of 137.44%. The business had revenue of $186.90 million for the quarter, compared to the consensus estimate of $242.82 million. During the same period last year, the business posted ($1.71) EPS. The firm’s revenue for the quarter was up 37.6% compared to the same quarter last year. On average, research analysts anticipate that Alnylam Pharmaceuticals will post -7.1 EPS for the current year.

In other Alnylam Pharmaceuticals news, Director Steven M. Paul sold 15,000 shares of the stock in a transaction on Friday, April 1st. The shares were sold at an average price of $170.69, for a total value of $2,560,350.00. Following the sale, the director now directly owns 1,000 shares in the company, valued at $170,690. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 1.40% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Amundi Pioneer Asset Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 12.6% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 149,659 shares of the biopharmaceutical company’s stock valued at $13,986,000 after purchasing an additional 16,733 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Alnylam Pharmaceuticals by 35.9% during the third quarter. Victory Capital Management Inc. now owns 55,878 shares of the biopharmaceutical company’s stock worth $10,550,000 after buying an additional 14,756 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in shares of Alnylam Pharmaceuticals by 5.4% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 10,313 shares of the biopharmaceutical company’s stock worth $1,947,000 after acquiring an additional 528 shares in the last quarter. Deutsche Bank AG grew its stake in shares of Alnylam Pharmaceuticals by 6.5% in the 3rd quarter. Deutsche Bank AG now owns 282,162 shares of the biopharmaceutical company’s stock worth $53,275,000 after acquiring an additional 17,319 shares in the last quarter. Finally, Advisor Group Holdings Inc. grew its position in Alnylam Pharmaceuticals by 5.1% during the third quarter. Advisor Group Holdings Inc. now owns 5,430 shares of the biopharmaceutical company’s stock valued at $1,025,000 after buying an additional 262 shares during the period. Institutional investors own 92.39% of the company’s stock.

Alnylam Pharmaceuticals Company Profile (Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Further Reading

The Fly logo

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.